Fresenius Medical Care

Akorn shares slip after court rules that Fresenius can cancel its buyout of the generic drugmaker

Fresenius scrapped the merger after an investigation found Akorn had a history of fraudulent product data submissions

Scales of justice statue
The Delaware Supreme Court upheld a previous ruling in favor of Fresenius

Shares of Akorn Inc (NASDAQ:AKRX) slipped double digits after a judge ruled that German health care company Fresenius Medical Care (NYSE:FMS) had sufficient cause to end its $4.8 billion bid for the company.

Akorn shares plummeted about 28% to $4.05 in Monday afternoon trading while Fresenius shares were down nearly 9% to $35.73.

READ: Akorn's stock soars after FDA approves ANDA for eyelash treatment Bimatoprost

After the ink on the agreement had dried, an independent investigation revealed that generic drugmaker Akorn had a history of fraudulent product data submissions.

Fresenius, a provider of kidney dialysis care, sought to end the agreement.

Judge Travis Laster found in October that the termination of the merger was valid, citing Akorn’s compliance issues.

The judge also found that Akorn had failed to continue operating as normal after inking the deal.

Laster wrote that Akorn's "magnitude of inaccuracies would reasonably be expected to result in a material adverse effect," as per a Reuters report.

Akorn stood its ground and appealed the decision, claiming that it was a breach of a binding merger agreement and that Fresenius was suffering from buyer’s remorse.

The Delaware Supreme Court was not swayed, issuing an order that upheld Judge Laster’s findings, as per a Bloomberg report.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee




Quick facts: Fresenius Medical Care

Price: $33.61

Market: NYSE
Market Cap: $20.36 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

18 hours, 44 minutes ago

2 min read